LYNPARZA pancreas cancer Japan Post-Marketing Surveillance (PMS)

Study identifier:D081FC00004

ClinicalTrials.gov identifier:NCT04889404

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

LYNPARZA Tablets 100 mg, 150mg General drug use-results study in patients on maintenance treatment after platinum-based chemotherapy for BRCA mutated curatively unresectable pancreas cancer

Medical condition

Pancreatic neoplasms

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

130

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 22 May 2021
Estimated Primary Completion Date: 30 Sept 2025
Estimated Study Completion Date: 30 Sept 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria